No Detail Found!

Pharmacist‑perceived barriers to pharmaceutical care of chronic and end‑stage kidney disease patients in Saudi Arabia

Author(s)
Amal K. Suleiman Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Maryam Melaibari Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Turkiah Alkhaldi Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Sara Almuhisen Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Samar Alharbi Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Abeer Kharshid Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Amany Alboghdadly Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Sireen Shilbayeh Department of Pharmaceutical Practices, Pharmacy College, Princess Nora bint Abdul Rahman University,Riyadh, Kingdom of,Saudi Arabia
Abstract
Objective: The aim of this study is to explore pharmacists' attitudes regarding pharmaceutical care in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. Methods: A cross-sectional questionnaire-based study was conducted among Saudi pharmacists between October 2012 and October 2014. A convenient sampling technique was employed in the five Saudi Kingdom regions: Central, West, East, North, and South. The target sample was 200 pharmacists based on a calculation of the power of sample with an 85% confidence level. SPSS, version 20®, was used to descriptively analyze the data. The Kruskal-Wallis test was applied to highlight the significant responses. A P < 0.05 was considered statistically significant. Results: Of the 200 questionnaires distributed, 162 were completed; a response rate 81.0%. Based on the results, pharmacists in Saudi generally had positive attitudes and beliefs toward pharmaceutical care in CKD and ESRD due to a complicated disease state with multiple drug and nondrug therapies (69.1%); this finding indicated that this type of pharmaceutical care requires that more time is dedicated to patients (69.7%). The results showed that 40.8% of pharmacists were familiar with National Kidney FoundationK-idney Disease Outcomes Quality Initiative clinical practice guidelines. Most pharmacists either agreed or strongly agreed that implementing this type of pharmaceutical care will have a positive economic impact on patients' families and the health system. The physician-pharmacist relationship is also considered to be a major barrier for pharmacist intervention given that physicians have primary responsibility for modifying the patients' treatment plans. Conclusion: The contribution of pharmacists in CKD and ESRD will continue to grow as their clinical knowledge improves. Saudi pharmacists believe that the pharmaceutical care is an essential component of managing CKD and ESRD patients.
Publication Details
Page(s) 54-60
Published Journal: Archives of Pharmacy Practice, Volume: 7, Issue: 2, Year: 2016

Request the full text from PASTIC

Keywords
Beliefs, Saudi Arabia, pharmaceutical care, Kidney disease, Attitudes
References
Schieppati A,Remuzzi G .2005 .Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. Kidney Int Suppl, 68 : S71-0.
Bethesda M. US .2011 .Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End‑Stage Renal Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, : 10.
Abegunde DO,Mathers CD,Adam T,Ortegon M,Strong K. .2007 .The burden and costs of chronic diseases in low‑income and middlei‑ncome countries. Lancet, 370 : 19293-8.
Danovitch GM .2009 .Lippincott Williams. , : .
Mirkov S. .2009 .Implementation of a pharmacist medication review clinic for haemodialysis patients. N Z Med J, 122 : 25-37.
Alkatheri AM .2004 .Pharmacist effectiveness in reducing medication‑related problems in dialysis patients. Saudi Pharm J, 12 : 54-9.
Nguyen TV .2007 .The consultant pharmacist's role in dialysis: An introduction. Consult Pharm, 22 : 1035-44.
Schmid H,Hartmann B,Schiffl H B .2009 .Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: A critical review of the literature. Eur J Med Res, 14 : 185-90.
Nissenson AR,Collins AJ,Hurley J,Petersen H,Pereira BJ,Steinberg EP .2001 .Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns. J Am Soc Nephrol, 12 : 1713-20.
Kopple JD .2001 .National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. American journal of kidney diseases, 37 : S66-S70.
Al‑Sayyari AA,Shaheen FA .2011 .End stage chronic kidney disease in Saudi Arabia. A rapidly changing scene. Saudi Med J, 32 : 339-46.
Manley HJ,Cannella CA,Bailie GR,St Peter WL. M e GR .2005 .d i c a t i o n ‑ re l a t e d p ro b l e m s i n a m b u l a t o r y hemodialysis patients: A pooled analysis. Am J Kidney Dis, 46 : 669-80.
. .The National Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for All Stages of Chronic Kidney Disease; 2013. [Last accessed on 2015 Dec, 24 : .
Alsultan MS,AH MS .2013 .Hospital pharmacy practice in Saudi Arabia: Drug monitoring and patient education in the Riyadh region. Saudi Pharm J, 21 : 361-70.
Aljbouri TM .2013 .Impact of clinical pharmacist on cost of drug therapy in the ICU. Saudi Pharm J, 21 : 371-4.
Stemer G,Lemmens‑Gruber R. .2011 .Clinical pharmacy activities in chronic kidney disease and end‑stage renal disease patients: A systematic literature review. BMC Nephrol, 12 : 35.
0

Citations

0

Downloads

13

Views